Grace Therapeutics (NASDAQ:GRCE) Stock Moved Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Grace Therapeutics (NASDAQ:GRCE – Free Report) from a strong sell rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

GRCE has been the subject of a number of other reports. Zacks Research raised shares of Grace Therapeutics to a “hold” rating in a research note on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Read Our Latest Research Report on Grace Therapeutics

Grace Therapeutics Stock Performance

Shares of NASDAQ GRCE opened at $1.81 on Friday. The firm has a market capitalization of $38.08 million, a price-to-earnings ratio of -1.47 and a beta of 0.43. The stock has a 50 day moving average price of $2.01 and a 200 day moving average price of $2.74. Grace Therapeutics has a 52-week low of $1.67 and a 52-week high of $5.18.

Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04.

Institutional Investors Weigh In On Grace Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Grace Therapeutics in the second quarter worth about $85,000. Pale Fire Capital SE bought a new position in shares of Grace Therapeutics during the 1st quarter worth approximately $175,000. Maven Securities LTD purchased a new stake in Grace Therapeutics during the second quarter valued at approximately $454,000. Bank of America Corp DE purchased a new position in Grace Therapeutics in the second quarter worth $1,123,000. Finally, Renaissance Technologies LLC grew its holdings in Grace Therapeutics by 87.9% in the first quarter. Renaissance Technologies LLC now owns 243,910 shares of the company’s stock worth $1,129,000 after purchasing an additional 114,129 shares during the last quarter. 6.08% of the stock is currently owned by hedge funds and other institutional investors.

Grace Therapeutics Company Profile

(Get Free Report)

Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders. The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Recommended Stories

Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.